4,636 results match your criteria Japanese Journal of Clinical Oncology [Journal]


Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.

Jpn J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Background: Anti-programmed cell death protein 1 monoclonal antibodies (αPD-1mAbs) have been shown to be effective for advanced malignant melanoma. Treatment with αPD-1mAbs can also cause immune-related adverse events (irAEs). However, clinical predictive factors for treatment responses or irAE risk remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy201DOI Listing
February 2019
1 Read

Salvage surgery for small cell lung cancer after chemoradiotherapy.

Jpn J Clin Oncol 2019 Feb 8. Epub 2019 Feb 8.

Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.

There are few reports on the use of salvage surgery for small cell lung cancer (SCLC). Five patients who underwent resection of post-chemoradiotherapy residual lesion/local reprogression of SCLC between 2005 and 2017 were included in the study. We retrospectively reviewed their surgical outcomes and prognosis to assess the feasibility and potential efficacy of salvage surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz010DOI Listing
February 2019
1 Read

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.

Jpn J Clin Oncol 2019 Feb 8. Epub 2019 Feb 8.

Tokyo Medical and Dental University, Tokyo, Japan.

Objective: We aimed to clarify the clinical practice and outcomes of first-line cetuximab-containing chemotherapy in patients with metastatic colorectal cancer. Efficacy and safety were evaluated in each group classified by the European Society for Medical Oncology Guidelines 2012.

Methods: This prospective observational study included patients with previously untreated metastatic colorectal cancer from 158 centers in Japan who started first-line cetuximab-containing chemotherapy from January 2012 to June 2013 and were followed for up to 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy189DOI Listing
February 2019
1 Read

Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.

Jpn J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India.

Aims: To investigate Ki-67 index with regard to its ability to predict achievement of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patient.

Material And Methods: It was a prospective observational study, conducted in Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Center (RGCIRC), New Delhi from February 2014 to March 2016. A total of 134 patients with Stage II/III breast cancer who underwent NACT followed by surgery at our center were enrolled and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz012DOI Listing
February 2019

Histologic variants associated with biological aggressiveness and poor prognosis in patients treated with radical cystectomy.

Jpn J Clin Oncol 2019 Feb 8. Epub 2019 Feb 8.

Department of Urology, Kitasato University School of Medicine, Kanagawa 252-0374, Japan.

Background: The prognostic value of histologic variants (HV) after radical cystectomy (RC) remains controversial. We evaluated the clinicopathological features and prognosis in patients with pure urothelial carcinoma (UC) and HV following RC.

Methods: From 1990 to 2015, 286 patients with bladder cancer were treated with RC at six Kitasato University-affiliated hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz015DOI Listing
February 2019

Overview of current and future systemic therapy for metastatic renal cell carcinoma.

Jpn J Clin Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Since the 2000s, there have been dramatic advances in the treatment of metastatic renal cell carcinoma (mRCC), including drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The first VEGF inhibitors approved for mRCC were sorafenib and sunitinib. Subsequently, two mTOR inhibitors (everolimus and temsirolimus) and other VEGF inhibitors (pazopanib and axitinib) were approved. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyz013DOI Listing
February 2019
2 Reads

Recurrent metastatic occult melanoma - Long-term remission after detection of the primary tumor by FDG-PET/CT.

Jpn J Clin Oncol 2019 Jan 31. Epub 2019 Jan 31.

Jena University Hospital, Clinic of Nuclear Medicine, Am Klinikum 1, Jena, Germany.

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyz006DOI Listing
January 2019
1 Read

Testis cancer incidence rates in the world from the Cancer Incidence in Five Continents XI.

Jpn J Clin Oncol 2019 Feb;49(2):199-200

Center for Cancer Registries, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz007DOI Listing
February 2019

Problems, goals and solutions reported by cancer patients participating in group problem-solving therapy.

Jpn J Clin Oncol 2019 Jan 31. Epub 2019 Jan 31.

Toyonaka Municipal Hospital, Osaka, Japan.

Background: The purpose of the present study was to categorize and develop lists of contents of problems, goals, solution plans generated through the brainstorming work in therapy, and selected solutions for execution, that treated in problem-solving therapy (PST) for cancer patients in clinical settings, and to describe their characteristics. Additionally, examining the associations of problem domains with characteristics of participants, was also aimed.

Methods: We conducted content analysis using records of thirty-one cancer patients (M = 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy191DOI Listing
January 2019

Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden.

Jpn J Clin Oncol 2019 Jan 31. Epub 2019 Jan 31.

Department of Third Internal Medicine, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan.

The introduction of a chimeric anti-CD20 monoclonal antibody, rituximab, for the treatment of follicular lymphoma (FL) has dramatically improved the prognosis of this disease. Despite advances in therapy, the disease remains incurable with current standard therapeutic strategies. For advanced-stage and high-tumor-burden FL patients, a combination of rituximab with chemotherapy has improved the overall survival rates, and subsequent rituximab maintenance following successful rituximab-based chemotherapy induction also prolongs progression-free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz008DOI Listing
January 2019
1 Read

Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.

Jpn J Clin Oncol 2019 Jan 31. Epub 2019 Jan 31.

Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.

Objective: Lung cancer is the most common causes of cancer death worldwide and patients with non-small-cell lung cancer (NSCLC) have various prognosis. We conducted this study to identify the prognostic predictors and establish a prognostic index score (PIS) for patients with Stage I NSCLC after stereotactic body radiation therapy (SBRT).

Methods: A total of 131 consecutive patients with Stage I NSCLC who underwent SBRT in our institute were analyzed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy205DOI Listing
January 2019
1 Read

Controversies in relation to neck management in N0 early oral tongue cancer.

Jpn J Clin Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Head and Neck Surgery, National Cancer Center Hospital East, Chiba, Japan.

The standard local treatment for early-stage tongue cancer with no clinical lymph node metastases is partial glossectomy. The frequency of occult lymph node metastasis is ~20-30%. Thus, whether prophylactic neck dissection with glossectomy or glossectomy alone should be performed has been a controversial issue since the 1980s. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy196DOI Listing
January 2019

TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions.

Jpn J Clin Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.

The staging classification of gynaecological malignancies has been revised by the International Federation of Gynecology and Obstetrics (FIGO) and has been subsequently reviewed by the FIGO Committee on Gynecologic Oncology, the International Union for Cancer Control TNM Committee and the American Joint Committee on Cancer. The major change in the eighth edition of TNM classification of gynaecological malignant tumours is integrated staging for ovarian, fallopian tube and primary peritoneal carcinoma, whereas the seventh edition distinguished 'ovary and primary peritoneal carcinoma' and 'Fallopian tube carcinoma'. Furthermore, the new edition describes a prognostic factor grid for vulvar, cervical, endometrial and ovarian, fallopian tube and primary peritoneal carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy206DOI Listing
January 2019
1 Read

Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis.

Jpn J Clin Oncol 2018 Dec 20. Epub 2018 Dec 20.

Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Objective: This study was conducted to evaluate the efficacy and toxicity of extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy in patients with cervical cancer with positive para-aortic lymph nodes (PALN).

Methods: From September 2007 to December 2014, a total of 59 patients who had cervical cancer with para-aortic lymph node metastasis were treated with concurrent chemoradiotherapy at our institution. A dose of 45-50. Read More

View Article

Download full-text PDF

Source
http://fdslive.oup.com/www.oup.com/pdf/production_in_progres
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy184DOI Listing
December 2018
3 Reads

Validation of the Integrated Palliative care Outcome Scale (IPOS) - Japanese Version.

Jpn J Clin Oncol 2019 Jan 22. Epub 2019 Jan 22.

Section of Liaison Psychiatry and Palliative Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.

Background: To improve palliative care practice, the need for patients-reported outcome measures is increasing globally. The Integrated Palliative care Outcome Scale (IPOS) is a streamlined outcome scale developed to comprehensively evaluate patients' distress. The goal of this study is to assess the reliability and validity of IPOS-Japanese version in cancer patients. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy203DOI Listing
January 2019
13 Reads

A case of early gastric cancer in a patient with splenic vein angioplany.

Jpn J Clin Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Gastroenterological Surgery, Kagawa University, Kagawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy207DOI Listing
January 2019

Prognostic significance of the presence of tertiary Gleason grade 5 in robot-assisted radical prostatectomy specimens in Japanese patients with clinically localized prostate cancer.

Jpn J Clin Oncol 2019 Jan 11. Epub 2019 Jan 11.

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Background: The aim of this study was to study the prognostic significance of tertiary Gleason grade (TGG) 5 in patients with clinically localized prostate cancer treated with robot-assisted radical prostatectomy (RARP).

Methods: A total of 600 Japanese patients who underwent RARP for clinical stage T1-3N0M0 prostate cancer were evaluated. TGG5 was evaluated according to the International Society of Urological Pathology criterion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy194DOI Listing
January 2019

Editorial.

Authors:
Hideo Kunitoh

Jpn J Clin Oncol 2019 Jan;49(1):1-2

Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan Editor-in-Chief, Japanese Journal of Clinical Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy183DOI Listing
January 2019
2 Reads

Construction and validation of a simple scoring system for stage III colorectal cancer recurrence (SiS-SCORE). A case control study.

Jpn J Clin Oncol 2019 Jan 4. Epub 2019 Jan 4.

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City, Japan.

Background: Stage III colorectal cancer is an indication for adjuvant chemotherapy; however, there is no definite view on the selection of regimen. If the recurrence can be predicted, it can serve as the indicator of regimen selection. The present study aimed to predict the recurrence of stage III colorectal cancer by constructing a simple scoring system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy192DOI Listing
January 2019

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

Jpn J Clin Oncol 2019 Feb;49(2):190-194

Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.

A randomized, controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S-1 with upfront surgery for patients planned resection of pancreatic cancer. Patients were enrolled after the diagnosis of resectable or borderline resectable by portal vein involvement pancreatic cancer with histological confirmation. They were randomly assigned to either neoadjuvant chemotherapy or upfront surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy190DOI Listing
February 2019

Salvage radiation therapy for prostate cancer patients after prostatectomy.

Jpn J Clin Oncol 2019 Jan 4. Epub 2019 Jan 4.

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Objectives: The aim of this study was to identify risk factors to predict a biochemical recurrence (BCR) in patients treated with salvage radiation therapy (SRT) after radical prostatectomy (RP).

Methods: We retrospectively reviewed 122 Japanese patients who received SRT for BCR after RP. Using uni- and multivariate Cox proportional hazard models, we identified the predictive factors of BCR after SRT. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy195DOI Listing
January 2019
22 Reads

Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma.

Jpn J Clin Oncol 2019 Feb;49(2):195-198

Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Chiba, Japan.

According to fluorescent in situ hybridization, t(11;14) is the most common cytogenetic abnormality in amyloid light-chain (AL) amyloidosis, but its prevalence in patients with AL amyloidosis and concurrent multiple myeloma (MM) remains unknown. We aimed to examine the prevalence of t(11;14) and the differences in clinical characteristics of patients with t(11;14) who had AL amyloidosis with or without concurrent MM. We retrospectively analyzed 40 patients with AL amyloidosis between January 2008 and January 2018 at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy202DOI Listing
February 2019

Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma.

Jpn J Clin Oncol 2019 Jan 4. Epub 2019 Jan 4.

Gastrointestinal Medical Oncology Division, Kochi Health Sciences Center, Kochi City, Kochi, Japan.

Background: The eighth edition of the tumor-node-metastasis classification of malignant tumors updates cancer staging according to the evidence accumulated in the last 8 years since the release of the tumor-node-metastasis seventh edition. This review focuses on the new staging system.

Methods: The eight edition was compared with the seventh edition as well as the Japanese Classification of Colorcetal, Appendiceal, and Anal carcinoma ninth edition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy198DOI Listing
January 2019

Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD).

Jpn J Clin Oncol 2018 Dec 24. Epub 2018 Dec 24.

Clinical Oncology Division, Kochi Health Sciences Center, Kochi, Japan.

A randomized phase III trial was initiated in May 2017 to confirm the superiority of post-operative therapy with capecitabine and oxaliplatin over observation in terms of relapse-free survival in patients with curatively resected small bowel adenocarcinoma. Total 150 patients will be enrolled from 20 Japanese institutions over a period of 6.5 years. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy188DOI Listing
December 2018
7 Reads

A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.

Jpn J Clin Oncol 2019 Feb;49(2):121-129

Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama.

Objective: Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy. This double-blind, randomized, Phase II study investigated the dose-response of oral netupitant in Japanese patients receiving highly emetogenic chemotherapy.

Methods: Chemotherapy-naïve patients were randomized (1:1:1) to a single oral netupitant 30-, 100- or 300-mg dose before chemotherapy initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy161DOI Listing
February 2019

Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy.

Jpn J Clin Oncol 2018 Dec 20. Epub 2018 Dec 20.

Department of Radiology, Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Honkomagome, Bunkyo-ku, Tokyo, Japan.

Objective: While external beam radiotherapy boost has been one of the standard management options for locally advanced cervical cancer that is not treatable with intracavitary brachytherapy, its efficacy remains unclear. We assessed clinical outcomes in Japanese patients with cervical cancer who underwent external beam radiotherapy alone and identified related prognostic factors.

Methods: Patients treated with definitive external beam radiotherapy for cervical cancer unsuitable for intracavitary brachytherapy, including whole pelvic irradiation and external beam radiotherapy boost, were retrospectively examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy187DOI Listing
December 2018

Laryngeal cancer incidence rates in the world from the Cancer Incidence in Five Continents XI.

Jpn J Clin Oncol 2019 Jan;49(1):100-101

Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy193DOI Listing
January 2019

A population-based cohort study to evaluate the effectiveness of lung cancer screening using low-dose CT in Hitachi city, Japan.

Jpn J Clin Oncol 2019 Feb;49(2):130-136

Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.

Objectives: To evaluate the effectiveness of lung cancer screening using low-dose computed tomography for the general population, we conducted a retrospective cohort study of screening for participants among Hitachi residents.

Materials And Methods: Citizens aged 50-74 who underwent low-dose computed tomography screening at least once during 1998-2006 were defined as the computed tomography group, and those who underwent X-ray screening at least once during the same period, but did not receive low-dose computed tomography screening throughout the follow-up period, were defined as the XP group. We investigated the lung cancer incidence rate, mortality rate and all-cause mortality rate for both groups from the first lung cancer screening to the end of 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366936PMC
February 2019
1 Read

Cancer stem cells in relation to treatment.

Jpn J Clin Oncol 2018 Dec 12. Epub 2018 Dec 12.

Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

The classical cancer therapies, including chemotherapy and radiation therapy, can initially show good results and tumor shrinkage; however, for most cancer patients disease recurrence is a common event. This tumor regrowth following therapy is now thought to depend on a small population of cancer stem cells (CSCs), which, similar to other stem cells, have the capacity for self-renewal and multipotent differentiation. Cancer stem cells have been identified based on cell surface protein expression in many tumor types, and for all diseases studied, this specific cell population is required for serial transplantation in animal models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy186DOI Listing
December 2018
2 Reads

Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan.

Jpn J Clin Oncol 2019 Feb;49(2):174-182

Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.

Background: Application of next-generation DNA sequencing (NGS) has recently become increasingly common in the field of clinical oncology in several countries around the world. In Japan also, a system for applying NGS to routine clinical practice is gradually being established. During this process, we introduced in Japan the tumor-profiling MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy173DOI Listing
February 2019
4 Reads

TNM classification of malignant tumors (Breast Cancer Study Group).

Jpn J Clin Oncol 2018 Dec 12. Epub 2018 Dec 12.

Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy182DOI Listing
December 2018
2 Reads

Population-based cohort study assessing the efficacy of cervical cytology (Pap smear) and human papillomavirus (HPV) testing as modalities for cervical cancer screening.

Jpn J Clin Oncol 2018 May;48(5):495-498

Department of Obstetrics and Gynecology, Keio University School of Medicine.

In cervical cancer screening, several trials have shown that human papillomavirus (HPV) testing or combined HPV testing and cytology leads to earlier detection of cervical intraepithelial neoplasia Grade 3 or worse (CIN3+) compared with cytology alone. However, the availability of similar evidence in our country remains limited. In 2013, 34 local governments were selected to administer a cervical cancer screening program utilizing either cytology alone or in combination with HPV testing. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/article/48/5/495/4919546
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy025DOI Listing
May 2018
10 Reads

Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys.

Jpn J Clin Oncol 2019 Feb;49(2):137-145

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.

Background: We investigated the practice patterns of surgery for advanced ovarian cancer (AOC) through relevant international surveys.

Methods: After searching for 878 studies on surgery for AOC till 2017, we extracted 18 questions with similar query and answer formats from eight studies. Among them, 5 and 13 were classified as comprehensive and procedure information. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy175DOI Listing
February 2019
15 Reads

What is the appropriate communication style for family members confronting difficult surrogate decision-making in palliative care?: A randomized video vignette study in medical staff with working experiences of clinical oncology.

Jpn J Clin Oncol 2019 Jan;49(1):48-56

Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan.

Background: The family members of terminally ill patients are often requested to make difficult surrogate decisions during palliative care. This study sought to clarify the appropriate communication style for physicians as perceived by family members confronting difficult surrogate decision-making.

Methods: This experimental psychological study used scripted videos. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy178DOI Listing
January 2019
1 Read

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Jpn J Clin Oncol 2019 Jan;49(1):29-36

Department of Medical Oncology, Kindai University Hospital, Ohno-higashi, Osaka, Japan.

Background: The FLAURA study was a multicenter, double-blind, Phase 3 study in which patients with previously untreated epidermal growth factor receptor mutation-positive advanced non-small-cell lung carcinoma were randomized 1:1 to oral osimertinib 80 mg once daily or standard-of-care (gefitinib 250 mg or erlotinib 150 mg, once daily) to compare safety and efficacy. In the overall FLAURA study, significantly better progression-free survival was shown with osimertinib versus standard-of-care.

Methods: Selected endpoints, including progression-free survival (primary endpoint), overall survival, objective response rate, duration of response and safety were evaluated for the Japanese subset of the FLAURA study. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322567PMC
January 2019
19 Reads

Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer.

Jpn J Clin Oncol 2019 Feb;49(2):165-173

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Background: Nanoparticle albumin-bound paclitaxel is indicated for the treatment of patients with lung cancer. It can induce interstitial lung disease, but the incidence of nanoparticle albumin-bound paclitaxel-associated interstitial lung disease in clinical practice has not been determined. We investigated the incidence of interstitial lung disease in patients with lung cancer who had received nanoparticle albumin-bound paclitaxel therapy at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy180DOI Listing
February 2019
1 Read

Co-operative groups in the development of chemotherapy for gastric cancer.

Jpn J Clin Oncol 2018 Dec 1. Epub 2018 Dec 1.

Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.

In the multimodality treatment strategy for gastric cancer, chemotherapy has an important role in conferring survival benefit. For the last three decades, great progress has been achieved in adjuvant and palliative chemotherapy. Powerful combination regimens using doublet or triplet cytotoxic agents have been developed and new molecular targeted drugs, including trastuzumab and ramucirumab, have been introduced in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy176DOI Listing
December 2018
1 Read

Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy.

Jpn J Clin Oncol 2019 Jan;49(1):22-28

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Objective: Over the past decade, several studies have highlighted that axillary lymph node ratio (ratio of involved over excised axillary lymph nodes) was a superior predictor for survival outcomes compared with ypN staging. Thus, this study aimed to integrate the prognostic value of axillary lymph node ratio to improve individualized prediction of survival in node-positive breast cancer patients after neoadjuvant chemotherapy.

Methods: A clinical data of 339 node-positive breast cancer patients after neoadjuvant chemotherapy from two independent centers were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy181DOI Listing
January 2019
8 Reads

Thanking All Peer Reviewers.

Authors:

Jpn J Clin Oncol 2018 Dec;48(12):1031-1033

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/article/48/12/1031/5209634
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy169DOI Listing
December 2018

JJCO Paper of the Year and Highly Commended Paper.

Authors:

Jpn J Clin Oncol 2018 Dec;48(12):1034

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy168DOI Listing
December 2018

JJCO Best Reviewer Award.

Authors:

Jpn J Clin Oncol 2018 Dec;48(12):1035

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy167DOI Listing
December 2018

Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study.

Jpn J Clin Oncol 2019 Jan;49(1):87-91

Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy174DOI Listing
January 2019
10 Reads

Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.

Jpn J Clin Oncol 2019 Jan;49(1):92-95

Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy177DOI Listing
January 2019
3 Reads

Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.

Jpn J Clin Oncol 2018 Nov 20. Epub 2018 Nov 20.

Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Oncolytic virus therapy is a promising new option for cancer. It utilizes genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming normal cells. T-VEC (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in 2015 and subsequently approved in Europe in 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy170DOI Listing
November 2018
11 Reads

Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan.

Jpn J Clin Oncol 2019 Jan;49(1):63-68

Department of Medical Oncology, Japanese Red Cross Medical Center, Japan.

Background: Adjuvant tegafur/uracil (UFT) chemotherapy is recommended for patients with completely resected Stage I non-small cell lung cancer (NSCLC) in Japan. A Phase III trial, the Japan Clinical Oncology Group (JCOG) 0707, comparing the survival benefit of UFT and S-1 (tegafur/gimeracil/oteracil) for this population is being conducted. However, the selection of patients in the randomized clinical trial (RCT) may not represent the real-world population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyy165DOI Listing
January 2019
14 Reads

Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study.

Jpn J Clin Oncol 2019 Feb;49(2):153-159

Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Nishihara, Japan.

Background: Cutaneous adverse reactions are frequently induced by mogamulizumab. Cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and severe photosensitivity related to mogamulizumab have been reported. This study investigated whether severe radiation-induced dermatitis occurred in patients undergoing radiotherapy after the administration of mogamulizumab for adult T-cell leukaemia/lymphoma. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy172DOI Listing
February 2019
14 Reads

Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.

Jpn J Clin Oncol 2019 Feb;49(2):160-164

Department of Medical Oncology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.

Background: Radiation therapy might modify the cancer immune environment to enhance the antitumor effect of immune checkpoint inhibitors. We performed a feasibility study of nivolumab following stereotactic radiation therapy for chemotherapy pretreated advanced non-small-cell lung cancer.

Patients And Methods: Pretreated advanced/recurrent non-small-cell lung cancer patients received stereotactic radiation therapy to one of the disease sites. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy171DOI Listing
February 2019
16 Reads

Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma.

Jpn J Clin Oncol 2019 Feb;49(2):146-152

Department of Radiotherapy & Oncology, PGIMER, Chandigarh.

Objective(s): This study aimed to retrospectively evaluate the toxicity and clinical outcomes in patients of locally advanced cervical cancer treated with three-dimensional conformal radiotherapy (3DCRT) and concurrent chemotherapy.

Material And Methods: Two hundred and ten newly diagnosed patients of locally advanced cervical cancer of FIGO 2009 Stage II-III treated with 3DCRT (46 Gy/23 fractions/4½ weeks) and weekly concurrent Cisplatin (40 mg/m2), from January 2013 to 2015 were analyzed. A planning computed tomography was performed and contouring was done according to published guidelines. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy164DOI Listing
February 2019
9 Reads

Loss of psoas major muscle volume during systemic chemotherapy is related to worse prognosis in testicular cancer.

Jpn J Clin Oncol 2019 Feb;49(2):183-189

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Objective: In several cancers, the loss of skeletal muscle is well associated with oncological outcome. However, its effect is unknown in testicular cancer. This study evaluated the prognostic impact of psoas major muscle volume loss during systemic chemotherapy. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy166DOI Listing
February 2019
16 Reads

A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906.

Jpn J Clin Oncol 2019 Jan;49(1):57-62

Graduate School of Medicine, Kyoto University Kyoto, Japan.

Objective: To evaluate the safety of hypofractionated whole breast irradiation in Japanese women after breast-conserving surgery.

Methods: Japanese women who had invasive breast cancer with a clinical tumor size ≤3 cm, pN0-1c and a negative inked margin were enrolled. Hypofractionated whole breast irradiation (42. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy160DOI Listing
January 2019
11 Reads